HR negative + HER-2 positive

Among patients with a solitary extracranial metastasis from breast cancer, TNBC was associated with the poorest OS and DPFS rates. Identification of other significant prognostic factors for oligometastatic breast cancer patients may inform guidelines for metastasis directed treatments.

In our study, a third of patients with stage II-III hormone receptor-negative and HER2-positive breast cancer had a complete pathological response after only three cycles of neoadjuvant systemic therapy. A complete response on breast MRI could help identify early complete responders in patients who had hormone receptor negative tumours. An imaging-based strategy might limit the duration of chemotherapy in these patients, reduce side-effects, and maintain quality of life if confirmed by the analysis of the 3-year event-free survival primary endpoint. Better monitoring tools are needed for patients with hormone receptor-positive and HER2-positive breast cancer.

Txnrd1High MDA-MB-231 cells exhibit significant ROS generation and reduced viability after doxorubicin treatment compared to Txnrd1Low MCF7 cells. Corroborating with findings from meta-analysis, Txnrd1 depletion leads to decreased survival, enhanced sensitivity to radiation induced killing, poor scratch-wound healing, and reduced invasion potential in MDA-MB-231 cells. Thus, Txnrd1 appears to be a potential predictor of recurrence, metastasis and therapy response in breast cancer patients.

P1/2, N=29, Recruiting, University of Florida | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 | Suspended --> Recruiting

P1/2, N=29, Suspended, University of Florida

This study suggests an unlikely add-on effect of an anthracycline-based regimen for NAC in HER2-positive breast cancer. Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer.

P1/2, N=29, Recruiting, University of Florida | Trial completion date: Dec 2024 --> Jun 2024

Molecular dissection of triple-positive breast cancer might provide the rational for additional therapeutic strategies and the identification of promising biomarkers. This review summarizes data on systemic treatment efficacy from major clinical trials and perspectives for future clinical research in triple-positive breast cancer.

No abstract available

The biological subtype of breast cancer with regional metastasis in most cases remains stable among the cases of the entire sample. Discordance of the subtype is most often observed in cases with a hormone receptor-negative Her2-positive subtype of the primary tumor.

P1/2, N=29, Recruiting, University of Florida | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023

TQB2440 and trastuzumab plus docetaxel is a feasible and effective neoadjuvant therapy for early-stage HR negative HER2-positive breast cancer, showing high pCR rate and acceptable cardiotoxicity. These results support a further random controlled trial testing for dual anti-HER2 therapy using TQB2440 in neoadjuvant or adjuvant therapy of HER2 positive breast cancer.

P1/2, N=29, Recruiting, University of Florida | Suspended --> Recruiting

P1/2, N=29, Suspended, University of Florida | Recruiting --> Suspended

The WSG-ADAPT-HER2+/HR- trial showed good survival rates in patients with a pathological complete response after de-escalated 12-week trastuzumab plus pertuzumab with or without weekly paclitaxel. Omission of further chemotherapy did not affect invasive disease-free survival in patients with a pathological complete response. 12 weeks of weekly paclitaxel plus dual HER2 blockade could be an efficacious de-escalated neoadjuvant regimen in patients with hormone receptor-negative, HER2-positive early breast cancer with high pathological complete response rates and good 5-year outcomes. Further trials of this approach are ongoing.

With aggressive trimodality therapy and a multidisciplinary team approach, IBC patients with supraclavicular nodal involvement experience excellent locoregional control and good survival. Definitive regional nodal radiation without supraclavicular dissection spares patients’ increased morbidity and should be considered even in the setting of residual radiologic supraclavicular disease after neoadjuvant systemic therapy.

This predictive model might aid in clinical-decision making of patients with positive margins who actually require a widening procedure after intraoperative and/or definitive histology.

Ten patients were treated with 4 courses of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), followed by 4 courses of docetaxel with trastuzumab and pertuzumab (HPD). The rate of pCR (ypT0/is and ypN0) was 81.8%, and this outcome was better than the NeoSphere trial and the TRYPHAENA trial. As a result, our study suggested an additional therapeutic effect of 4 courses of FEC followed by 4 courses of HPD.

Our study provides an updated population-level estimate of the incidence and survival for patients with brain metastases at the diagnosis of breast cancer, thus may help early identification, prognostic stratification and treatment planning for such patients.

P1/2, N=29, Recruiting, University of Florida | Not yet recruiting --> Recruiting

Several mechanistic studies have also been conducted in in vivo models, but the exact mechanism by which eosinophils act in the presence of breast cancer is still unknown. Further studies on this subject are desirable, in order to understand their role at the cellular level, identify related biomarkers and/or possibly search for new therapeutic targets.

Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.

The clinical characteristics of breast cancer in Korea have been changing, and national databases can improve our understanding of the disease characteristics of Korean women. Therefore, updating the KBCS registry is important for the effective management of breast cancer in Korea.

No abstract available

A mastectomy and axillary lymph node sampling were performed for a local control as the tumor did not respond to four cycles of triweekly trastuzumab combined with S-1...After 10 day fixation by a tie-over dressing, the wound healed without complications. This procedure is a simple method for closing a large defect after mastectomy preventing both the dog-ear deformity and a new wound scarring of a donor site.

Background: Lapatinib (L) plus trastuzumab (T) with weekly paclitaxel significantly increased the pathologic complete response (pCR) rate (51.3%) compared with either anti-human epidermal growth factor receptor 2 (HER2) drug alone (24.7%% for L, 29.5% for T)...After surgery, patients received 3 cycles of fluorouracil, epirubicin and cyclophosphamide followed by 34 weeks of the same assigned neoadjuvant anti-HER2 therapy... Long-term follow up analysis confirms that patients with pCR have a significant higher survival probability than those who did not achieve pCR, supporting pCR as an early indicator of long-term outcome in HER2-positive disease. These effects were particularly seen in patients with negative hormone receptors and dual anti-HER2 treatment. Although overall survival rates were not significantly different between arms, patients who reached pCR with L + T therapy were nearly doubled compared to the patients in the single agent arms.

This large multicenter pooled data analysis suggests that a standardized protocol using image-guided VAB of a tumor bed measuring 2 cm or smaller with 6 or more representative samples allows reliable prediction of residual disease. These results could inform the design of de-escalation trials in NACT exceptional responders testing the safety of eliminating surgery.

Conclusion We found that although ILC was similar to IDC and IMC based on tumor stage, tumor grade, risk category distribution, they demonstrated different predictors of high-risk ODX. Overall DFS was best in patients with IMC and patients with ILC, classic variant, however, when stratified based on RS scores the results were variable.

Prognostic superiority of YAP/TAZ expression depended on hormone receptor status. Cases with synchronous over-expression of YAP/TAZ and HER3 suffered poor survival, which revealed the potential effect of YAP/TAZ-HER2/HER3 crosstalk in prognosis of HER2-positive patients.

As a second agent, pertuzumab showed significantly higher DFS and OS. Clinical efficacy can be increased for hormone receptor-negative tumors by including a second HER2-targeted agent to the treatment regimen. For hormone receptor-positive cases with basal disease, it is acceptable to reduce the risk of cardiotoxicity by shortening the duration of trastuzumab.

Our results illustrate, that a biomarker status switch after neoadjuvant treatment occurs in 28% of cases. Reassessment of hormone and HER2 receptor status subsequent to neoadjuvant treatment is still under discussion, with regard to post-neoadjuvant treatment. Nevertheless, it may have potential benefits for patients regarding individualization of treatment and potentially even patient outcome.

Our results illustrate, that a biomarker status switch after neoadjuvant treatment occurs in 28% of cases. Reassessment of hormone and HER2 receptor status subsequent to neoadjuvant treatment is still under discussion, with regard to post-neoadjuvant treatment. Nevertheless, it may have potential benefits for patients regarding individualization of treatment and potentially even patient outcome.

Our results illustrate, that a biomarker status switch after neoadjuvant treatment occurs in 28% of cases. Reassessment of hormone and HER2 receptor status subsequent to neoadjuvant treatment is still under discussion, with regard to post-neoadjuvant treatment. Nevertheless, it may have potential benefits for patients regarding individualization of treatment and potentially even patient outcome.

Our results illustrate, that a biomarker status switch after neoadjuvant treatment occurs in 28% of cases. Reassessment of hormone and HER2 receptor status subsequent to neoadjuvant treatment is still under discussion, with regard to post-neoadjuvant treatment. Nevertheless, it may have potential benefits for patients regarding individualization of treatment and potentially even patient outcome.

BCS after NAC is not associated with differences in surgical outcomes, when compared to a contemporary PBCS cohort in the no-ink-on-tumor era. With NAC in selected patients, surgeons can expect similar re-operation, complications requiring intervention, and lower volumes of excision.

ALK may be involved in breast cancer tumorigenesis, and ALK pathway signature score may serve as a prognostic biomarker for breast cancer.

On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence. Adverse reactions in ≥ 30% of patients receiving pertuzumab were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting. From a regulatory standpoint, the benefits of the addition of pertuzumab to adjuvant treatment outweighed the risks for patients with EBC at high risk of recurrence.

Patients had a low incidence of cancer recurrence at the NAC after NSM and immediate breast reconstruction in this study. The findings suggest that multifocal or multicentric disease, hormone receptor-negative/ERBB2-positive subtype, high histologic grade, and positive extensive intraductal component should be considered before determining the NSM procedure.

The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

Our finding demonstrates here for the first time that high expression of Aurora A was notably correlated with early recurrence and poor overall survival in obesity patients with early breast cancer. The Aurora A-Cyclin B1 axis could be a potential promising therapeutic target for cancer intervention and therapy.

Trastuzumab duocarmazine shows notable clinical activity in heavily pretreated patients with HER2-expressing metastatic cancer, including HER2-positive trastuzumab emtansine-resistant and HER2-low breast cancer, with a manageable safety profile. Further investigation of trastuzumab duocarmazine for HER2-positive breast cancer is ongoing and trials for HER2-low breast cancer and other HER2-expressing cancers are in preparation.

In addition, a lower prevalence of triple-negative and a higher prevalence of luminal-A breast carcinomas was observed in screen-detected tumors. Moreover, a literature review pointed out important differences in subrogate molecular types in screen-detected breast carcinomas among reported series, mainly due to study design, technical issues and racial differences.